DeepMed Research

PV FIT LIMITED

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma

Phase 1

Recruiting

Conditions: Cholangiocarcinoma

Interventions: Drug: GNS561 + Trametinib

First Posted Date: 2023-05-24

Last Posted Date: 2025-05-23

Lead Sponsor: Genfit

Target Recruit Count: 74

Registration Number: NCT05874414

Locations: 🇺🇸
LA Cancer Network, Los Angeles, California, United States
🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

and more 6 locations

Nitazoxanide Pharmacokinetic Parameters in Renal Impaired Subjects

Phase 1

Completed

Conditions: Renal Impairment
Renal Disease
Kidney Disease

Interventions: Drug: Nitazoxanide

First Posted Date: 2022-05-10

Last Posted Date: 2022-10-28

Lead Sponsor: Genfit

Target Recruit Count: 77

Registration Number: NCT05368935

Locations: 🇺🇸
Panax Clinical Research, Miami Lakes, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients

Phase 1

Completed

Conditions: Moderate Hepatic Impairment
Severe Hepatic Impairment
Liver Diseases

Interventions: Drug: Nitazoxanide

First Posted Date: 2021-11-11

Last Posted Date: 2022-10-14

Lead Sponsor: Genfit

Target Recruit Count: 25

Registration Number: NCT05116826

Locations: 🇺🇸
Panax Clinical Research, Miami Lakes, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

Elafibranor Pharmacokinetic Parameters in Elderly Healthy Volunteers

Phase 1

Completed

Conditions: Geriatrics
Healthy

Interventions: Drug: elafibranor

First Posted Date: 2019-11-21

Last Posted Date: 2020-08-13

Lead Sponsor: Genfit

Target Recruit Count: 21

Registration Number: NCT04171752

Locations: 🇫🇷
BIOTRIAL, Rennes, France

Study to Investigate the Potential Drug-Drug Interaction Between Elafibranor and Indomethacin

Phase 1

Completed

Conditions: Drug-drug Interaction

Interventions: Drug: elafibranor
Drug: CHRONO-INDOCID

First Posted Date: 2019-06-14

Last Posted Date: 2020-08-13

Lead Sponsor: Genfit

Target Recruit Count: 26

Registration Number: NCT03985969

Locations: 🇫🇷
Eurofins Optimed Clinical Pharmacology Unit, Gières, France

Study to Evaluate the Effect of Elafibranor on Hepatic Lipid Composition in Subjects With Nonalcoholic Fatty Liver (NAFL)

Phase 2

Terminated

Conditions: Non-Alcoholic Fatty Liver

Interventions: Drug: elafibranor 120mg
Drug: Placebo

First Posted Date: 2019-05-16

Last Posted Date: 2020-08-31

Lead Sponsor: Genfit

Target Recruit Count: 17

Registration Number: NCT03953456

Locations: 🇳🇱
NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht, Netherlands

Elafibranor, PK and Safety in Children and Adolescents 8 to 17 Years of Age With Non Alcoholic Steatohepatitis (NASH)

Phase 2

Terminated

Conditions: Non Alcoholic Steatohepatitis

Interventions: Drug: Elafibranor 120mg
Drug: Elafibranor 80mg

First Posted Date: 2019-03-21

Last Posted Date: 2021-10-28

Lead Sponsor: Genfit

Target Recruit Count: 10

Registration Number: NCT03883607

Locations: 🇺🇸
University of California, San Diego, California, United States
🇺🇸
Columbia University, New York, New York, United States

Elafibranor Pharmacokinetic Parameters in Renal Impaired Patients

Phase 1

Completed

Conditions: Renal Insufficiency
Pharmacokinetics
Kidney Diseases
Renal Impairment

Interventions: Drug: Elafibranor

First Posted Date: 2019-02-18

Last Posted Date: 2020-08-13

Lead Sponsor: Genfit

Target Recruit Count: 23

Registration Number: NCT03844555

Locations: 🇫🇷
Eurofins Optimed, Gières, France
🇷🇴
ARENSIA Exploratory Medicine Unit, Nephrology Hospital Dr. Carol Davilla, Bucharest, Romania

Elafibranor Pharmacokinetic Parameters in Hepatic Impaired Patients

Phase 1

Completed

Conditions: Hepatic Impairment
Liver Disease
Pharmacokinetics

Interventions: Drug: Elafibranor

First Posted Date: 2018-12-05

Last Posted Date: 2019-08-22

Lead Sponsor: Genfit

Target Recruit Count: 30

Registration Number: NCT03765671

Locations: 🇺🇸
inVentiv Health Clinical Research, Miami, Florida, United States
🇺🇸
Division of Clinical Pharmacology, University of Miami, Miami, Florida, United States

Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid

Phase 2

Completed

Conditions: Primary Biliary Cholangitis (PBC)

Interventions: Drug: Placebo
Drug: Elafibranor 80 mg
Drug: Elafibranor 120 mg

First Posted Date: 2017-04-21

Last Posted Date: 2019-09-24

Lead Sponsor: Genfit

Target Recruit Count: 45

Registration Number: NCT03124108

Locations: 🇪🇸
Hospital De La Sant Creu St. Pau, Barcelona, Spain
🇬🇧
King's College Hospital, London, United Kingdom
🇺🇸
Cleveland Clinic Florida, Weston, Florida, United States

and more 21 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy